In the foreseeable future, will the growth of the company require sufficient equity financing so that the larger number of shares outstanding will largely cancel the existing stockholders' benefit from this anticipated growth? - Phillip Fisher
Every industry has its norm. In bioscience investing, it's typical for most young therapeutic innovators to operate with neither revenues nor earnings for many years. This is because the drugs are still in development. Nevertheless, the dynamic is different for medical diagnostic operators. That is to say, they usually have an approved product and thereby generate sales. After all,